Azelnidipine and glucose tolerance: Possible indications and treatment selection for hypertensive patients with metabolic disorders

Expert Review of Cardiovascular Therapy

Volumn 13, Issue 1, 2015, Pages 23-31

  Shimada, Kazunori ^a   Miyauchi, Katsumi ^a   Daida, Hiroyuki ^a  

^a JUNTENDO UNIVERSITY   (Japan)

Author keywords

anti atherogenic effect; anti inflammatory effect; anti oxidative effect; azelnidipine; cardiovascular and metabolic disorders; essential hypertension; glucose tolerance; insulin resistance

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; AZELNIDIPINE; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; AZETIDINE 2 CARBOXYLIC ACID; DIHYDROPYRIDINE DERIVATIVE;

ANTIHYPERTENSIVE THERAPY; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; DRUG INDICATION; ESSENTIAL HYPERTENSION; GLUCOSE INTOLERANCE; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; HUMAN; HYPERTENSION; INSULIN RESISTANCE; INSULIN SENSITIVITY; META ANALYSIS (TOPIC); METABOLIC DISORDER; MORBIDITY; NONHUMAN; OXIDATIVE STRESS; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SYMPATHETIC NERVE; SYMPATHETIC TONE; ANALOGS AND DERIVATIVES; COMPLICATION; DRUG EFFECTS; METABOLIC DISEASES;

AZETIDINECARBOXYLIC ACID; CALCIUM CHANNEL BLOCKERS; DIHYDROPYRIDINES; GLUCOSE INTOLERANCE; HUMANS; HYPERTENSION; METABOLIC DISEASES; RENIN-ANGIOTENSIN SYSTEM;

EID: 84919459099     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/14779072.2015.986464     Document Type: Review

References (89)

1. Ruilope LM. Can the effectiveness of hypertension management be improved Expert Rev Cardiovasc Ther 2013;11: 689-95
2. Ferrannini E, Cushman WC. Diabetes and hypertension: the bad companions. Lancet 2012;380:601-10
3. Ohira T, Iso H. Cardiovascular disease epidemiology in Asia: an overview. Circ J 2013;77:1646-52
4. Taylor EN, Hu FB, Curhan GC. Antihypertensive medications and the risk of incident type 2 diabetes. Diabetes Care 2006;29:1065-70
5. Sowers JR, Epstein M, Frohlich ED. Diabetes, hypertension, and cardiovascular disease: an update. Hypertension 2001;37: 1053-9
6. Zhou MS, Schulman IH. Prevention of diabetes in hypertensive patients: results and implications from the VALUE trial. Vasc Health Risk Manag 2009;5:361-8
7. Oizumi K, Nishino H, Koike H, et al. Antihypertensive effects of CS-905, a novel dihydropyridine Ca++ channel blocker. Jpn J Pharmacol 1989;51:57-64
8. Oizumi K, Nishino H, Miyamoto M, et al. Beneficial renal effects of CS-905, a novel dihydropyridine calcium blocker, in SHR. Jpn J Pharmacol 1989;51:501-8
9. Oizumi K, Miyamoto M, Koike H. Antihypertensive effect of CS-905, a novel dihydropyridine calcium blocker, in conscious hypertensive dogs. Jpn J Pharmacol 1990;53:264-6
10. Kario K, Sato Y, Shirayama M, et al. Inhibitory effects of azelnidipine tablets on morning hypertension. Drugs R D 2013;13: 3-73
11. Azelnidipine. CS 905, Calblock, RS 9054. Drugs R D 2003;4:122-5
12. Nada T, Nomura M, Koshiba K, et al. Clinical study with azelnidipine in patients with essential hypertension. Antiarteriosclerotic and cardiac hypertrophy-inhibitory effects and influence on autonomic nervous activity. Arzneimittelforschung 2007;57:698-704
13. Iwai M, Li HS, Chen R, et al. Calcium channel blocker azelnidipine reduces glucose intolerance in diabetic mice via different mechanism than angiotensin receptor blocker olmesartan. J Pharmacol Exp Ther 2006;319:1081-7
14. Guo Q, Minami N, Mori N, et al. Effects of antihypertensive drugs and exercise training on insulin sensitivity in spontaneously hypertensive rats. Hypertens Res 2008;31:525-33
15. Kain V, Kumar S, Puranik AS, Sitasawad SL. Azelnidipine protects myocardium in hyperglycemia-induced cardiac damage. Cardiovasc Diabetol 2010;9:82
16. Fukao K, Shimada K, Hiki M, et al. Effects of calcium channel blockers on glucose tolerance, inflammatory state, and circulating progenitor cells in non-diabetic patients with essential hypertension: a comparative study between azelnidipine and amlodipine on glucose tolerance and endothelial function-a crossover trial (AGENT). Cardiovasc Diabetol 2011;10:79
17. Daikuhara H, Kikuchi F, Ishida T. The combination of OLmesartan and a CAlcium channel blocker (azelnidipine) or candesartan and a calcium channel blocker (amlodipine) in type 2 diabetic hypertensive patients: the OLCA study. Diab Vasc Dis Res 2012;9:280-6
18. Yamagishi S, Inagaki Y, Nakamura K, Imaizumi T. Azelnidipine, a newly developed long-acting calcium antagonist, inhibits tumor necrosis factor-alpha-induced interleukin-8 expression in endothelial cells through its anti-oxidative properties. J Cardiovasc Pharmacol 2004;43:724-30
19. Abe T, Fuse I, Narita M, et al. Combination use of immune complexes and a Ca2(+) channel blocker azelnidipine enhances interleukin-12 p40 secretion without T helper type 17 cytokine secretion in human monocyte-derived dendritic cells. Clin Exp Immunol 2009;156:405-12
20. Kojima T, Miyauchi K, Yokoyama T, et al. Azelnidipine and amlodipine anti-coronary atherosclerosis trial in hypertensive patients undergoing coronary intervention by serial volumetric intravascular ultrasound analysis in Juntendo University (ALPS-J). Circ J 2011;75:1071-9
21. DeFronzo RA, Abdul-Ghani M. Assessment and treatment of cardiovascular risk in prediabetes: impaired glucose tolerance and impaired fasting glucose. Am J Cardiol 2011;108:3B-24B
22. Medalie JH, Papier CM, Goldbourt U, Herman JB. Major factors in the development of diabetes mellitus in 10,000 men. Arch Intern Med 1975;135: 811-17
23. Chen G, McAlister FA, Walker RL, et al. Cardiovascular outcomes in Framingham participants with diabetes: the importance of blood pressure. Hypertension 2011;57: 891-7
24. Zhang Y, Lee ET, Devereux RB, et al. Prehypertension, diabetes, and cardiovascular disease risk in a population-based sample: the Strong Heart Study. Hypertension 2006;47:410-14
25. Conen D, Ridker PM, Mora S, et al. Blood pressure and risk of developing type 2 diabetes mellitus: the Women's Health Study. Eur Heart J 2007;28:2937-43
26. Stahl CH, Novak M, Lappas G, et al. High-normal blood pressure and long-term risk of type 2 diabetes: 35-year prospective population based cohort study of men. BMC Cardiovasc Disord 2012;12:89
27. Bosch J, Lonn E, Pogue J, HOPE/HOPETOO Study Investigators. Long-term effects of ramipril on cardiovascular events and on diabetes: results of the HOPE study extension. Circulation 2005;112:1339-46
28. Franklin SS, Wachtell K, Papademetriou V, et al. Cardiovascular morbidity and mortality in hypertensive patients with lower versus higher risk: a LIFE substudy. Hypertension 2005;46:492-9
29. Yusuf S, Ostergren JB, Gerstein HC, et al. Candesartan in Heart Failure-Assessment of Reduction in Mortality and Morbidity Program Investigators. Effects of candesartan on the development of a new diagnosis of diabetes mellitus in patients with heart failure. Circulation 2005;112:48-53
30. Brown MJ, Palmer CR, Castaigne A, et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000;356:366-72
31. Barzilay JI, Davis BR, Cutler JA, et al. ALLHAT Collaborative Research Group. Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 2006;166: 2191-201
32. Julius S, Weber MA, Kjeldsen SE, et al. The Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) trial: outcomes in patients receiving monotherapy. Hypertension 2006;48:385-91
33. Verdecchia P, Reboldi G, Angeli F, et al. Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension 2004;43:963-9
34. Miyazaki T, Shimada K, Iwama Y, et al. Insulin response to oral glucose load is associated with coronary artery disease in subjects with normal glucose tolerance. J Atheroscler Thromb 2008;15:6-12
35. Yamasaki Y, Kawamori R, Matsushima H, et al. Asymptomatic hyperglycaemia is associated with increased intimal plus medial thickness of the carotid artery. Diabetologia 1995;38:585-91
36. Standl E, Erbach M, Schnell O. What should be the antihypertensive drug of choice in diabetic patients and should we avoid drugs that increase glucose levels Pro and Cons. Diabetes Metab Res Rev 2012;28:60-6
37. Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 2007;369: 201-7
38. Yusuf S, Gerstein H, Hoogwerf B, et al. HOPE Study Investigators. Ramipril and the development of diabetes. JAMA 2001;286:1882-5
39. Julius S, Weber MA, Kjeldsen SE, et al. The Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) trial: outcomes in patients receiving monotherapy. Hypertension 2006;48:385-91
40. Vardeny O, Uno H, Braunwald E, et al. Prevention of Events with an ACE Inhibitor (PEACE) Investigators. Opposing effects of b blockers and angiotensin-converting enzyme inhibitors on development of new-onset diabetes mellitus in patients with stable coronary artery disease. Am J Cardiol 2011;107:1705-9
41. NAVIGATOR Study Group. McMurray JJ, Holman RR, Haffner SM, et al. Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med 2010;362:1477-90
42. Shen L, Shah BR, Reyes EM, et al. Role of diuretics, b blockers, and statins in increasing the risk of diabetes in patients with impaired glucose tolerance: reanalysis of data from the NAVIGATOR study. BMJ 2013;347:f6745
43. Ueda S, Morimoto T, Ando ST, et al. DIME Investigators. A randomised controlled trial for the evaluation of risk for type 2 diabetes in hypertensive patients receiving thiazide diuretics: diuretics In the Management of Essential hypertension (DIME) study. BMJ Open 2014;4:e004576
44. Alderman MH. New onset diabetes during antihypertensive therapy. Am J Hypertens 2008;21:493-9
45. Grossman E, Verdecchia P, Shamiss A, et al. Diuretic treatment of hypertension. Diabet Care 2011(Suppl 2):S313-19
46. Karnes JH, Gong Y, Pacanowski MA, et al. Impact of TCF7L2 single nucleotide polymorphisms on hydrochlorothiazide-induced diabetes. Pharmacogenet Genom 2013;23:697-705
47. Karnes JH, McDonough CW, Gong Y, et al. Association of KCNJ1 variation with change in fasting glucose and new onset diabetes during HCTZ treatment. Pharmacogenom J 2013;13:430-6
48. Fonseca VA. Effects of beta-blockers on glucose and lipid metabolism. Curr Med Res Opin 2010;26:615-29
49. Noto H, Goto A, Tsujimoto T, Noda M. Effect of calcium channel blockers on incidence of diabetes: a meta-analysis. Diabetes Metab Syndr Obes 2013;6:257-61
50. Sada T, Mizuno M, Miyama T, et al. Pharmacological characteristics of azelnidipine, a long-acting calcium antagonist, having vascular affinity (No. 2)-antihypertensive effect and pharmacokinetics in spontaneously hypertensive rats (SHR) [in Japanese]. Jpn Pharmacol Ther 2002;30: 711-20
51. Oizumi K, Nishino H, Koike H, et al. Antihypertensive effects of CS-905, a novel dihydropyridine Ca++ channel blocker, in SHR. Jpn J Pharmacol 1989;51:57-64
52. Fujisawa M, Yorikane R, Matsuoka Y, et al. The pharmacological differences in antianginal effects of long-lasting calcium channel blockers: azelnidipine and amlodipine. J Cardiovasc Pharmacol 2013;61:63-9
53. Rhodes DG, Sarmiento JG, Herbette LG. Kinetics of binding of membrane-active drugs to receptor sites. Diffusion-limited rates for a membrane bilayer approach of 1,4-dihydropyridine calcium channel antagonists to their active site. Mol Pharmacol 1985;27:612-23
54. Nakashima M, Kawabata K, Sasahara K, Phase I study of CS-905, a new calcium antagonist-III : a multiple dose study on healthy volunteers. [in Japanese]. Rinsho Iyaku 2000;16:191-205
55. Wellington K, Scott LJ. Azelnidipine. Drugs 2003;63:2613-21
56. Kuramoto K, Ichikawa S, Hirai A, et al. Azelnidipine and amlodipine: a comparison of their pharmacokinetics and effects on ambulatory blood pressure. Hypertens Res 2003;26:201-8
57. Arita M, Hashizume T, Tanigawa K, et al. A new Ca-antagonist, azelnidipine, reduced blood pressure during exercise without augmentation of sympathetic nervous system in essential hypertension: a randomized, double-blind, placebo-controlled trial. J Cardiovasc Pharmacol 1999;33:186-92
58. Yoshinaga K, Iimura O, Abe K, et al. Efficacy and safety of CS-905 (azelnidipine) monotherapy on essential hypertension in the long-term treatment [in Japanese]. Rinsho Iyaku 1999;15:943-83
59. Hirai A, Terano T, Saito Y. Efficacy and safety of CS-905 (azelnidipine) combination therapy on essential hypertension [in Japanese]. Rinsho Iyaku 1999;15:505-1545
60. Nikolopoulou A, Kadoglou NP. Obesity and metabolic syndrome as related to cardiovascular disease. Expert Rev Cardiovasc Ther 2010;10:933-9
61. Shinomiya K, Mizushige K, Fukunaga M, et al. Antioxidant effect of a new calcium antagonist, azelnidipine, in cultured human arterial endothelial cells. J Int Med Res 2004;32:170-5
62. Matsui T, Yamagishi S, Nakamura K, et al. Azelnidipine, a dihydropyridine-based calcium antagonist, inhibits angiotensin II-induced oxidative stress generation and downregulation of pigment epithelium-derived factor mRNA levels in microvascular endothelial cells. Drugs Exp Clin Res 2005;31:215-19
63. Manabe S, Okura T, Fukuoka T, Higaki J. Antioxidative effects of azelnidipine on mesangial cell proliferation induced by highly concentrated insulin. Eur J Pharmacol 2007;567:252-7
64. Jinno T, Iwai M, Li Z, et al. Calcium channel blocker azelnidipine enhances vascular protective effects of AT1 receptor blocker olmesartan. Hypertension 2004;43: 263-9
65. Yamamoto E, Lai ZF, Yamashita T, et al. Enhancement of cardiac oxidative stress by tachycardia and its critical role in cardiac hypertrophy and fibrosis. J Hypertens 2006;24:2057-69
66. Nakamura T, Sugaya T, Kawagoe Y, et al. Azelnidipine reduces urinary protein excretion and urinary liver-type fatty acid binding protein in patients with hypertensive chronic kidney disease. Am J Med Sci 2007;333:321-6
67. Ohmura C, Watada H, Shimizu T, et al. Calcium channel blocker, azelnidipine, reduces lipid hydroperoxides in patients with type 2 diabetes independent of blood pressure. Endocr J 2007;54:805-11
68. Ogawa S, Mori T, Nako K, Ito S. Combination therapy with renin-angiotensin system inhibitors and the calcium channel blocker azelnidipine decreases plasma inflammatory markers and urinary oxidative stress markers in patients with diabetic nephropathy. Hypertens Res 2008;31: 1147-55
69. Abe M, Maruyama N, Okada K, et al. Additive antioxidative effects of azelnidipine on angiotensin receptor blocker olmesartan treatment for type 2 diabetic patients with albuminuria. Hypertens Res 2011;34:935-41
70. Bhat T, Teli S, Rijal J, et al. Neutrophil to lymphocyte ratio and cardiovascular diseases: a review. Expert Rev Cardiovasc Ther 2013;11:55-9
71. Naito Y, Shimozawa M, Manabe H, et al. Azelnidipine, a new calcium channel blocker, inhibits endothelial inflammatory response by reducing intracellular levels of reactive oxygen species. Eur J Pharmacol 2006;546:11-18
72. Nakano K, Egashira K, Tada H, et al. A third-generation, long-acting, dihydropyridine calcium antagonist, azelnidipine, attenuates stent-associated neointimal formation in non-human primates. J Hypertens 2006;24:1881-9
73. Takahashi K, Shimokado K, Yoshida M. SDF-1-induced adhesion of monocytes to vascular endothelium is modulated by azelnidipine via protein kinase C inhibition. Eur J Pharmacol 2006;552:162-9
74. Zhao J, Ozawa K, Kyotani Y, et al. Azelnidipine inhibits cultured rat aortic smooth muscle cell death induced by cyclic mechanical stretch. PLoS One 2014;9: e102813
75. Miura R, Nakamura K, Miura D, et al. Cytokine reducing effect of azelnidipine in human peripheral blood mononuclear cells. Biol Pharm Bull 2010;33:1148-51
76. Yokokura H, Hiromatsu S, Akashi H, et al. Effects of calcium channel blocker azelnidipine on experimental abdominal aortic aneurysms. Surg Today 2007;37: 468-73
77. Kurobe H, Matsuoka Y, Hirata Y, et al. Azelnidipine suppresses the progression of aortic aneurysm in wild mice model through anti-inflammatory effects. J Thorac Cardiovasc Surg 2013;146:1501-8
78. Omote Y, Deguchi K, Kono S, et al. Synergistic neuroprotective effects of combined treatment with olmesartan plus azelnidipine in stroke-prone spontaneously hypertensive rats. J Neurosci Res 2014;92: 1330-7
79. Uzui H, Morishita T, Nakano A, et al. Effects of combination therapy with olmesartan and azelnidipine on serum osteoprotegerin in patients with hypertension. J Cardiovasc Pharmacol Ther 2014;19:304-9
80. Shokoji T, Fujisawa Y, Kiyomoto H, et al. Effects of a new calcium channel blocker, azelnidipine, on systemic hemodynamics and renal sympathetic nerve activity in spontaneously hypertensive rats. Hypertens Res 2005;28:1017-23
81. Kimura Y, Hirooka Y, Sagara Y, Sunagawa K. Long-acting calcium channel blocker, azelnidipine, increases endothelial nitric oxide synthase in the brain and inhibits sympathetic nerve activity. Clin Exp Hypertens 2007;29:13-21
82. Konno S, Hirooka Y, Araki S, et al. Azelnidipine decreases sympathetic nerve activity via antioxidant effect in the rostral ventrolateral medulla of stroke-prone spontaneously hypertensive rats. J Cardiovasc Pharmacol 2008;52:555-60
83. Nakamoto M, Ohya Y, Sakima A, et al. Azelnidipine attenuates cardiovascular and sympathetic responses to air-jet stress in genetically hypertensive rats. Hypertens Res 2007;30:359-66
84. Nagasu H, Satoh M, Fujimoto S, et al. Azelnidipine attenuates glomerular damage in Dahl salt-sensitive rats by suppressing sympathetic nerve activity. Hypertens Res 2012;35:348-55
85. Inomata J, Murai H, Kaneko S, et al. Differential effects of azelnidipine and amlodipine on sympathetic nerve activity in patients with primary hypertension. J Hypertens 2014;32:1898-904
86. Node K, Inoue T. Postprandial hyperglycemia as an etiological factor in vascular failure. Cardiovasc Diabetol 2009;8:23
87. Popa C, Netea MG, van Riel PL, et al. The role of TNF-alpha in chronic inflammatory conditions, intermediary metabolism, and cardiovascular risk. J Lipid Res 2007;48: 751-62
88. Ogihara T, Saruta T, Shimada K, Kuramoto K. A randomized, double-blind, four-arm parallel-group study of the efficacy and safety of azelnidipine and olmesartan medoxomil combination therapy compared with each monotherapy in Japanese patients with essential hypertension: the REZALT study. Hypertens Res 2009;32:1148-54
89. Rizos CV, Elisaf MS. Antihypertensive drugs and glucose metabolism. World J Cardiol 2014;6:517-30